TrialPath
Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193 · Olema Oncology, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors
About this study
Part 1A (Dose Escalation for OP-3136 Monotherapy): This part of the study will evaluate the safety, tolerability, and PK in a range of doses of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, administered orally once daily to participants with ER+ HER2- advanced or metastatic breast cancer (mBC), advanced or metastatic castration resistant prostate cancer (mCRPC), or advanced or metastatic non-small cell lung cancer (mNSCLC), and determine the maximum tolerated dose (MTD) and the recommended dose/regimen for expansion (RDE). Part 1B (Dose Escalation for OP-3136 in Combination with Fulvestrant): This part of the study will evaluate the safety and PK of OP-3136 administered in combination with fulvestrant in participants with ER+ HER2- mBC, and determine MTD and RDE for this combination. Part 1C (Dose Escalation for OP-3136 in Combination with Palazestrant): This part of the study will evaluate the safety and PK of OP-3136 administered in combination with palazestrant in participants with ER+ HER2- mBC, and determine MTD and RDE for this combination. Part 2A (Dose Expansion for OP-3136 Monotherapy): This part will evaluate two expansion cohorts at the monotherapy RDE from part 1 in participants with ER+ HER2- mBC and participants with mCRPC. Part 2B (Dose Expansion for OP-3136 in Combination with Fulvestrant OR Palazestrant): This part will evaluate the RDEs for OP-3136 in combination with fulvestrant from Part 1B OR the RDEs of OP-3136 in combination with palazestrant in an expansion cohort in participants with ER+ HER2- mBC.
Eligibility criteria
Key Inclusion Criteria: * Participants with advanced or metastatic ER+HER2- breast cancer, mCRPC, or NSCLC (Part 1) or advanced or metastatic ER+HER2- BC or mCRPC (Part 2). * Part 1A (Dose escalation for OP-3136 monotherapy): Participants must have a tumor that is unresectable or metastatic and for which life prolonging measures do not exist or available therapies are intolerable or no longer effective. * Part 1B (Dose escalation for OP-3136 in combination with fulvestrant): Participants with advanced or metastatic ER+ HER2- breast cancer that have progressed on or after at least 1 prior line of treatment that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting and must have received no more than 2 prior lines of endocrine therapy (one of which must be in combination with CDK4/6 inhibitor) and no more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced or metastatic setting. * Part 1C (Dose escalation for OP-3136 in combination with palazestrant): Participants with advanced or metastatic ER+ HER2- breast cancer that have progressed on or after at least 1 prior line of treatment that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting and must have received no more than 2 prior lines of endocrine therapy (one of which must be in combination with CDK4/6 inhibitor) and no more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced or metastatic setting. * Part 2A (Dose Expansion in ER+ HER2- mBC for OP-3136 monotherapy): Participants must have received up to 3 prior lines of endocrine therapy (one of which must be in combination with CDK4/6 inhibitor) and up to 1 prior line of chemotherapy or an antibody-drug conjugate. * Part 2A (Dose Expansion in mCRPC for OP-3136 monotherapy): Participants must have received up to 4 lines of prior systemic therapy for prostate cancer. Prior therapy must include treatment with an androgen receptor pathway inhibitor(s). * Part 2B (Dose Expansion in ER+ HER2- mBC for OP-3136 in combination with fulvestrant OR Dose Expansion in ER+ HER2- mBC for OP-3136 in combination with palazestrant): Participants must have progressed on or after at least 1 prior line of treatment that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting. Participants must have received no more than 2 prior lines of endocrine therapy in the advanced or metastatic setting and no more than 1 prior line of chemotherapy or an antibody-drug conjugate in the advanced or metastatic setting. Key Exclusion Criteria: * Prior therapy with KAT6A/B inhibitor in any treatment setting. * Participants with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term. * Known active or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require CNS-specific treatment, or participants who did not demonstrate clinical and radiologic stability during the last 2 months prior to the first dose of study treatment or require or are currently on steroid therapy for CNS metastases. * History of cerebral vascular disease, including transient ischemic attack, within 6 months prior to the first dose of study treatment. * History of or ongoing impaired cardiac function or clinically significant cardiac disease within 6 months prior to the first dose of study treatment. Note: Additional inclusion/exclusion criteria may apply.
Study design
Enrollment target: 180 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-12-16
Estimated completion: 2027-08-30
Last updated: 2026-11-20
Interventions
Drug: OP-3136Drug: FulvestrantDrug: Palazestrant
Primary outcomes
  • • Number of participants with dose-limiting toxicities in the Dose Escalation Arms (Up to 28 days)
  • • Incidence of adverse events and laboratory abnormalities (Up to 26 months)
Sponsor
Olema Oncology, Inc. · industry
Contacts & investigators
ContactThere may be multiple sites in this clinical trial Olema Oncology, Inc. · contact · clinical@olema.com · 415-651-7206
ContactOlema Medical Study Director · contact
InvestigatorMedical Director, MD · study_director, Olema Oncology, Inc.
All locations (25)
Banner MD Anderson Cancer CenterRecruiting
Gilbert, Arizona, United States
University of ColoradoRecruiting
Aurora, Colorado, United States
Florida Cancer SpecialistsRecruiting
Sarasota, Florida, United States
University Medical Center - New OrleansTerminated
New Orleans, Louisiana, United States
Massachusetts General HospitalRecruiting
Boston, Massachusetts, United States
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
START - MidwestRecruiting
Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
The Ohio State UniversityRecruiting
Columbus, Ohio, United States
SCRI Oncology PartnersRecruiting
Nashville, Tennessee, United States
Tennessee OncologyRecruiting
Nashville, Tennessee, United States
START - San AntonioRecruiting
San Antonio, Texas, United States
START - Mountain RegionRecruiting
West Valley City, Utah, United States
The Kinghorn Cancer CentreRecruiting
Darlinghurst, New South Wales, Australia
Liverpool HospitalRecruiting
Liverpool, New South Wales, Australia
Macquarie University Clinical Trials UnitRecruiting
Macquarie, New South Wales, Australia
Cancer Research South AustraliaRecruiting
Adelaide, South Australia, Australia
Institut De Cancerologie De L'ouestRecruiting
Saint-Herblain, Loire-Atlantique, France
Hôpital Paris Saint-JosephRecruiting
Paris, Paris, France
Institut Gustave RoussyRecruiting
Villejuif, Val-de-Marne, France
Queen Mary HospitalRecruiting
Hong Kong, Hong Kong, Hong Kong
START DublinRecruiting
Dublin, Dublin, Ireland
START - BarcelonaRecruiting
Barcelona, Barcelona, Spain
Start - FjdRecruiting
Madrid, Madrid, Spain
START Madrid - CIOCCRecruiting
Madrid, Madrid, Spain
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors · TrialPath